Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC

This study will test a new potential treatment for advanced esophageal squamous cell cancer (ESCC) for patients whose initial treatment has stopped working. Currently, the standard second-line treatment for this cancer is PD-1 inhibitors or chemotherapy alone, which is not very effective, allowing the cancer to grow again after just 1.6 to 3.4 months on average. Therefore, there is a strong need for more effective therapies. The new treatment is a type of drug called an antibody-drug conjugate (ADC). It is designed to target a specific protein called EGFR, which is found in high amounts on the surface of 50-70% of ESCC cancer cells and is linked to a poorer outlook for patients. This ADC works like a targeted delivery system: an antibody guides a powerful cell-killing drug directly to the cancer cells, aiming to destroy them while reducing harm to healthy cells. Although other drugs targeting EGFR have not successfully improved survival for ESCC patients, this new ADC offers a different and promising approach. The main goal of this study is to find out if this new EGFR-targeting ADC is effective in helping patients with advanced ESCC live longer without their cancer getting worse.

NCT Number	NCT07403136
Lead Sponsor	Fudan University
Conditions	Esophageal Squamous Cell Carcinoma
Enrollment	104 participants
Start Date	2026-04-30
Primary Completion	2027-08-01 (estimated)
Study Completion	2029-01-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-07